A practical reference on synthetic peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-25 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
=== Musculoskeletal conditions === In general, there is little evidence that electrotherapy is effective in the management of musculoskeletal conditions. In particular, there is no evidence that electrotherapy is effective in the relief of pain arising from osteoarthritis, and little to no evidence available to support electrotherapy for the management of fibromyalgia.
== Other activities == As an actress, Pansino appeared on Season 2 of VH1's Scream Queens, a reality series in which the prize was a role in one of the Saw films; she finished in 9th place. Following this, Pansino appeared in small roles on shows such as Parks and Recreation and CSI: Crime Scene Investigation. She voiced the role of Violet in the animated web series Broken Quest in 2013. In 2015, she made a cameo in the music video for "Dessert" by Dawin ft. Silentó. In 2016, she had a recurring voice role on the television series Emo Dad and also guest starred in the Disney Channel series Bizaardvark as herself. Pansino starred on the third season of YouTube Red's Escape the Night as The Jetsetter in 2018, the fourth season as The Socialite in 2019, and the later three-episode follow-up series as The Fitness Instructor in 2025. Pansino and the rest of the cast for both the third and fourth seasons were nominated for Streamy Awards. In 2023, she guest starred as a wedding planner on NCIS: Los Angeles, which she described as a "dream come true." Pansino is a classically trained singer. She released her debut single entitled, "Perfect Together", in 2015. Produced by Kurt Hugo Schneider, it was initially released as a single on iTunes, but a music video was released later the same year; as of 2019, it has over 20 million views. She has continued to post covers of popular songs on her YouTube channel, notably of songs like "Part of Your World" from the Disney movie The Little Mermaid.
5 August – The 18th century Crooked House, once known as "Britain's wonkiest pub", is gutted by a fire. The pub is demolished two days later. Police subsequently confirm they are treating the fire as arson. 6 August Secretary of State for Justice Alex Chalk confirms that the rule deducting living costs from compensation paid to people who have been wrongfully convicted will be scrapped. Greetings card retailer Clintons are to close around 20% of their outlets to cut back on expenditure. 7 August – The first group of asylum seekers to be housed on the Bibby Stockholm while they wait for the cases to be processed arrive on the barge following delays over safety concerns. 8 August The Police Service of Northern Ireland issues an apology after a data breach led to the details of its officers being published online. The Electoral Commission warns people to look out for unauthorised use of their data after revealing it was the victim of a "complex cyber-attack" in August 2021, which was not discovered until October 2022. The Joint Committee on Vaccination and Immunisation recommends the Autumn 2023 programme of COVID-19 booster vaccines should be routinely offered to all over-65s, as well as those under 65 in clinical risk groups, care home residents and frontline health workers. This marks a change from 2022 when all adults over 50 were offered the booster. The flu vaccine will also be offered to over 65s after the age was dropped to 50 during the pandemic.
== History and etymology == The first studies of proteins that could be regarded as proteomics began in 1974, after the introduction of the two-dimensional gel and mapping of the proteins from the bacterium Escherichia coli. Proteome is a blend of the words protein and genome. It was coined in 1994 by Marc Wilkins while he was a doctoral student at Macquarie University, which founded the first dedicated proteomics laboratory in 1995.
Sources: en.wikipedia.org
== Taxonomy == Although unnamed Ambrosiella-like fungi had previously been documented from the galleries and mycangia of native X. crassiusculus populations in central Japan, A. roeperi was first described as a novel species of ambrosia fungus by Harrington and McNew in 2014 based on isolations from beetles collected and trapped in the eastern United States, where it is invasive. It has not been assigned a common name at the time of this writing. All Ambrosiella are ambrosia beetle symbionts and belong to the family Ceratocystidaceae, which, where sexual stages are recognized, produce round, ostiolate (with a pore) fruiting bodies for their ascospores with a fine peridium (outer layer) and aseptate (lacking crosswalls) paraphyses (sterile tissue found among – and arising from the same surface as – spore-bearing cells). This family also includes Ceratocystis, representing several plant pathogens and sap-staining fungi, often transported by insects (including scolytine beetles); Chalaropsis, encompassing a few economically insignificant root diseases; Huntiella, primarily made up of saprobes associated with lesions on trees, transported by sap beetles and in one case an Ips bark beetle; Thielaviopsis, containing various agents of disease affecting monocots; Davidsoniella, comprising several species of tree pathogens, and Endoconidiophora, growing on conifers, producing disease and/or sap stain, and also often acting as a bark beetle associate.
== Disease relevance == The presence of serum prolidase in the blood is a good indicator of the presence and severity of many types of diseases. For instance, Type 2 Diabetes mellitus patients have elevated levels of serum prolidase. This is expected because high blood glucose leads to a decrease in collagen production and inflammatory cell generation, which depreciates wound healing ability. Furthermore, Rheumatoid Arthritis, Ankylosing spondylitis, and benign joint hypermobility syndrome have corresponded with low serum prolidase levels. Prolidase has become a prominent marker of cancer progression in patients with various types of cancer. Depending on the elevated levels of serum prolidase in the blood, physicians are able to determine tumor size, stage of cancer, and prognosis, all of which help significantly in treating these diseases. Analysis of serum prolidase levels has been used to detect the severity of liver disease in some instances. Research has indicated the correlation between chronic liver diseases and serum prolidase. For instance, one study suggested an increase in serum prolidase levels during the initial stages of cirrhotic liver fibrosis, followed by a decrease as the disease progressed. Moreover, analysis of serum prolidase levels in alcoholic hepatitis patients has displayed higher levels compared to cirrhosis patients. Serum prolidase is a highly necessary enzyme in the human body. Through its many functions, most notably collagen recycling, prolidase is widely used in the overall metabolism of humans.
=== Everton === On 20 July 2021, Townsend signed for fellow English club Everton on a two-year contract upon the expiry of his contract with Crystal Palace. Townsend made his debut on 14 August 2021, assisting Richarlison's goal as Everton came from behind to beat Southampton 3–1 on the opening day of the season. On 24 August 2021, Townsend scored the winning goal in an EFL Cup round two fixture against Huddersfield Town. On 13 September 2021, Townsend scored his first Premier League goal for Everton, smashing in a long-range effort from 30 yards to put Everton ahead as they went on to beat Burnley 3–1; this goal won him the Premier League Goal of the Month award. On 20 March 2022, Townsend was forced off the pitch in the 16th minute of an eventual 4–0 loss against former club Crystal Palace in the quarter-finals of the FA Cup, and was later revealed to have suffered an anterior cruciate ligament injury. Subsequently, he went on to miss the remainder of the 2021–22 season as well as the entirety of the 2022–23 season, after which he departed Everton at the conclusion of his contract, having not played in over 18 months.
Sources: en.wikipedia.org
Nuclear pharmacy focuses on preparing radioactive materials for diagnostic tests and for treating certain diseases. Nuclear pharmacists undergo additional training specific to handling radioactive materials, and unlike in community and hospital pharmacies, nuclear pharmacists typically do not interact directly with patients.
Gentle cleansing and coverage of the wound with antibiotic ointment or petrolatum is recommended until sutures are removed in instances of primary closure or local flap repairs. Depending on varying factors such as tension of the wound, anatomic site, and personal patient factors, this usually occurs 5-14 days after the operation. On the other hand, immobilization and non-adherent dressings may be required for skin grafts. This is more intensive postoperative care, and better outcomes in select locations, like on the nose or foot, are associated with delayed grafting. For certain areas of the body, like the concave surface of the ear, secondary intention healing (SIH) may be the best option for healing as it is associated with good cosmetic outcomes and lower complications in the appropriate cases. SIH involves leaving the wound to heal naturally, by itself, with no intervention (including no stitches or grafts). The wound heals while the patient monitors for healthy tissue formation and keeps the area clean with dressing changes. To reduce the risk of bleeding, patients are generally advised not to carry over 10 pounds of weight and avoid excessive physical activity for 2-3 days after the procedure. Minor complications (outlined above in the Risks and Complications section) rarely occur and patients are usually able to continue their normal activity within days of the operation.
== Historical uses == Especially in medieval times, the end of a chain could be attached to a chain tower or boom tower. This allowed safe raising or lowering of the chain, as they were often heavily fortified. By raising or lowering a chain or boom, access could be selectively granted rather than simply rendering the stretch of water completely inaccessible. The raising and lowering could be accomplished by a windlass mechanism or a capstan. Booms or chains could be broken by a sufficiently large or heavy ship, and this occurred on many occasions, including the siege of Damietta, the raid on the Medway and the Battle of Vigo Bay.A Frequently, however, attackers instead seized the defences and cut the chain or boom by more conventional methods. The boom at the siege of Derry, for example, was cut by sailors in a longboat. As a key portion of defences, booms were usually heavily defended. This involved shore-based chain towers, artillery batteries, or forts. In the Age of Sail, a boom protecting a harbour could have several ships defending it with their broadsides, discouraging assaults on the boom. On some occasions, multiple booms spanned a single stretch of water.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.